<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32436077</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2240-2993</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neurologica Belgica</Title><ISOAbbreviation>Acta Neurol Belg</ISOAbbreviation></Journal><ArticleTitle>Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.</ArticleTitle><Pagination><StartPage>1519</StartPage><EndPage>1523</EndPage><MedlinePgn>1519-1523</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13760-020-01382-7</ELocationID><Abstract><AbstractText>Since 2015, edaravone is the second drug available for the treatment of Amyotrophic lateral sclerosis (ALS). In this study we analyzed the characteristics and experience of ALS patients treated with this new medication in our country. Sixteen ALS patients were treated with edaravone infusions in three ALS clinics. Most of them were male, had a spinal onset of the disease and a definite diagnosis of ALS. Mean age at first infusion was 53.5&#xa0;years. Since the diagnosis of ALS, delay in starting treatment with edaravone was five times greater than that of riluzole. Edaravone therapy was usually initiated at a health care facility and was followed by domiciliary cycles. Adverse effects and the need of a special catheter for infusion were rare. Access to edaravone through health insurance was possible in only 43.8% of patients. Altogether, treatment access was limited but feasible and edaravone was well tolerated.</AbstractText><CopyrightInformation>&#xa9; 2020. Belgian Neurological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quarracino</LastName><ForeName>C</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9162-9626</Identifier><AffiliationInfo><Affiliation>Neurology Department, Instituto de Investigaciones M&#xe9;dicas Alfredo Lanari, Av. Combatientes de Malvinas 3150, Buenos Aires, Argentina. cecquarr@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendersky</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>III Normal Anatomy Department (Living Anatomy Laboratory), School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, Instituto Argentino de Investigaci&#xf3;n Neurol&#xf3;gica (IADIN), Uruguay 824, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Department, Instituto Argentino de Investigaci&#xf3;n Neurol&#xf3;gica (IADIN), Uruguay 824, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>G E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Neurology Department, ALS Clinic, Hospital Ramos Mej&#xed;a, Gral. Urquiza 609, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Acta Neurol Belg</MedlineTA><NlmUniqueID>0247035</NlmUniqueID><ISSNLinking>0300-9009</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004333" MajorTopicYN="N">Drug Administration Routes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse effects</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32436077</ArticleId><ArticleId IdType="doi">10.1007/s13760-020-01382-7</ArticleId><ArticleId IdType="pii">10.1007/s13760-020-01382-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oliveira AS, Pereira RD (2009) Amyotrophic lateral sclerosis (ALS): three letters that change the people&#x2019;s life. For ever. Arq Neuro-psiquiatr 67(3A):750&#x2013;782. https://doi.org/10.1590/s0004-282x2009000400040</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0004-282x2009000400040</ArticleId></ArticleIdList></Reference><Reference><Citation>Quarracino C, Segamarchi MC, Rodriguez GE (2019) Predictors of amyotrophic lateral sclerosis mimic syndrome. Acta Neurol Belg 119(2):253&#x2013;256. https://doi.org/10.1007/s13760-019-01135-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-019-01135-1</ArticleId><ArticleId IdType="pubmed">30972662</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH (2003) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Mot Neuron Disord 4(3):191&#x2013;206</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310002601</ArticleId></ArticleIdList></Reference><Reference><Citation>Edaravone Als 16 Study G (2017) A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener 18(sup1):11&#x2013;19. https://doi.org/10.1080/21678421.2017.1363780</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1363780</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39(2):733&#x2013;748. https://doi.org/10.1002/med.21528</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A (2006) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 7(4):241&#x2013;245. https://doi.org/10.1080/17482960600881870</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother 19(3):185&#x2013;193. https://doi.org/10.1080/14737175.2019.1581610</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1581610</ArticleId><ArticleId IdType="pubmed">30810406</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici MG, Shinohara Y (2013) Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 35(5):402&#x2013;418. https://doi.org/10.1159/000351753</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351753</ArticleId><ArticleId IdType="pubmed">23712178</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H, Edaravone ALSSG (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Front Degener 15(7&#x2013;8):610&#x2013;617. https://doi.org/10.3109/21678421.2014.959024</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505&#x2013;512. https://doi.org/10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone Als 17 Study G (2017) Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener 18(sup1):20&#x2013;31. https://doi.org/10.1080/21678421.2017.1362000</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1362000</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna A, Gizzi M, Bello L, Martinelli I, Bertolin C, Pegoraro E, Corbetta M, Soraru G, Edaravone Study G (2019) Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci 404:47&#x2013;51. https://doi.org/10.1016/j.jns.2019.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.06.006</ArticleId><ArticleId IdType="pubmed">31325668</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JM, Kim SY, Park D, Park JS (2019) Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. https://doi.org/10.1007/s10072-019-04055-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId><ArticleId IdType="pubmed">31686244</ArticleId><ArticleId IdType="pmc">7223963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C, Heiman-Patterson T, Kittrell P, Baranovsky T, McAnanama G, Bower L, Agnese W, Martin M (2019) Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotroph Lateral Scler Front Degener 20(7&#x2013;8):605&#x2013;610. https://doi.org/10.1080/21678421.2019.1645858</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1645858</ArticleId></ArticleIdList></Reference><Reference><Citation>Recommendation CDEC (2019) CADTH Canadian drug expert committee recommendation: edaravone (radicava&#x2014;Mitsubishi Tanabe Pharma Corporation). https://www.cadth.ca/sites/default/files/cdr/complete/sr0573-radicava-cdec-rec-march-29-2019.pdf</Citation></Reference><Reference><Citation>Hardiman O, van den Berg LH (2017) Edaravone: a new treatment for ALS on the horizon? Lancet Neurol 16(7):490&#x2013;491. https://doi.org/10.1016/S1474-4422(17)30163-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30163-1</ArticleId><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17(5):416&#x2013;422. https://doi.org/10.1016/S1474-4422(18)30054-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId><ArticleId IdType="pmc">5899963</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, Huiwang ZY, Qinwang M, He J (2019) Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci 40(2):235&#x2013;241. https://doi.org/10.1007/s10072-018-3653-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3653-2</ArticleId><ArticleId IdType="pubmed">30483992</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y (2018) Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurological Sci 11:11&#x2013;14. https://doi.org/10.1016/j.ensci.2018.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J (2019) Author response to a letter to the editor entitled: edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin). Amyotroph Lateral Scler Front Degener 20(3&#x2013;4):300&#x2013;302. https://doi.org/10.1080/21678421.2019.1582675</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582675</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmoy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH (2017) July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Front Degener 18(7&#x2013;8):471&#x2013;474. https://doi.org/10.1080/21678421.2017.1369125</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE (2019) Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Front Degener 20(3&#x2013;4):260&#x2013;263. https://doi.org/10.1080/21678421.2019.1572191</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572191</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>